Q3 2025 results: Net sales of $533 million (+6% at actual rates); diluted EPS $0.60 Core sales +6% CER (constant exchange rates) driven by QIAstat-Dx (+11% CER), QuantiFERON (+11% CER) and Sample ...
Q4 2025 Management View Gunjan Kedia, President, CEO & Director, reported "earnings per share of $1.26, an increase of approximately 18% year-over-year on an adjusted basis" and record net revenues of ...
Management anticipates the SWK transaction to scale the portfolio to $1.2 billion on a September 30 pro forma basis and optimize leverage at approximately 1.1x. “We anticipate this transaction will ...
Acquisition of $15M stone distributor on track to close before December 15; the multi-location business will add revenue, EBITDA, and scale in a fast-growing category. The deal, first announced in ...
Acquisition of $15M stone distributor on track to close before December 15; the multi-location business will add revenue, EBITDA, and scale in a fast-growing category. NEW YORK CITY, NEW YORK / ACCESS ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results